Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children

BACKGROUND: Typhoid fever caused by multidrug-resistant H58 Salmonella Typhi is an increasing public-health threat in sub-Saharan Africa. We present phase 3 efficacy data from an African trial of a Vi-polysaccharide typhoid conjugate vaccine (Vi-TCV). METHODS: Children aged 9 months to 12 years in B...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Patel, Priyanka D., Patel, Pratiksha, Liang, Yuanyuan, Meiring, James E., Misiri, Theresa, Mwakiseghile, Felistas, Tracy, J. Kathleen, Masesa, Clemens, Msuku, Harrison, Banda, David, Mbewe, Maurice, Henrion, Marc, Adetunji, Fiyinfolu, Simiyu, Kenneth, Rotrosen, Elizabeth, Birkhold, Megan, Nampota, Nginache, Nyirenda, Osward M., Kotloff, Karen, Gmeiner, Markus, Dube, Queen, Kawalazira, Gift, Laurens, Matthew B., Heyderman, Robert S., Gordon, Melita A., Neuzil, Kathleen M.
Formato: Artigo
Idioma:Inglês
Publicado em: Massachusetts Medical Society 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202713/
https://ncbi.nlm.nih.gov/pubmed/34525285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2035916
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados